Biotechnology Portfolio Biotechnology Fund Price Prediction
| FBIOX Fund | USD 17.96 0.30 1.64% |
Oversold Vs Overbought
45
Oversold | Overbought |
Biotechnology Portfolio fund price prediction is an act of determining the future value of Biotechnology Portfolio shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Biotechnology Portfolio's future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Biotechnology Portfolio and does not consider all of the tangible or intangible factors available from Biotechnology Portfolio's fundamental data. We analyze noise-free headlines and recent hype associated with Biotechnology Portfolio Biotechnology, which may create opportunities for some arbitrage if properly timed.
It is a matter of debate whether fund price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of Biotechnology Portfolio based on different types of headlines from major news networks to social media. The Biotechnology price prediction module provides an analysis of price elasticity to changes in media outlook on Biotechnology Portfolio over a specific investment horizon. Using Biotechnology Portfolio hype-based prediction, you can estimate the value of Biotechnology Portfolio Biotechnology from the perspective of Biotechnology Portfolio response to recently generated media hype and the effects of current headlines on its competitors.
This module is based on analyzing investor sentiment around taking a position in Biotechnology Portfolio. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in Biotechnology Portfolio to buy its mutual fund at a price that has no basis in reality. In that case, they are not buying Biotechnology because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell mutual funds at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Biotechnology Portfolio after-hype prediction price | USD 17.96 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as fund price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Biotechnology |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Biotechnology Portfolio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Biotechnology Portfolio After-Hype Price Prediction Density Analysis
As far as predicting the price of Biotechnology Portfolio at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Biotechnology Portfolio or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Mutual Fund prices, such as prices of Biotechnology Portfolio, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Biotechnology Portfolio Estimiated After-Hype Price Volatility
In the context of predicting Biotechnology Portfolio's mutual fund value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Biotechnology Portfolio's historical news coverage. Biotechnology Portfolio's after-hype downside and upside margins for the prediction period are 16.56 and 19.36, respectively. We have considered Biotechnology Portfolio's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Biotechnology Portfolio is very steady at this time. Analysis and calculation of next after-hype price of Biotechnology Portfolio is based on 3 months time horizon.
Biotechnology Portfolio Mutual Fund Price Prediction Analysis
Have you ever been surprised when a price of a Mutual Fund such as Biotechnology Portfolio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biotechnology Portfolio backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Fund price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Biotechnology Portfolio, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.01 | 1.39 | 0.00 | 0.00 | 1 Events / Month | 1 Events / Month | Very soon |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
17.96 | 17.96 | 0.00 |
|
Biotechnology Portfolio Hype Timeline
Biotechnology Portfolio is currently traded for 17.96. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Biotechnology is estimated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is estimated to be very small, whereas the daily expected return is currently at 0.01%. %. The volatility of related hype on Biotechnology Portfolio is about 579.17%, with the expected price after the next announcement by competition of 17.96. The company last dividend was issued on the 8th of April 2020. Assuming the 90 days horizon the next estimated press release will be very soon. Check out Biotechnology Portfolio Basic Forecasting Models to cross-verify your projections.Biotechnology Portfolio Related Hype Analysis
Having access to credible news sources related to Biotechnology Portfolio's direct competition is more important than ever and may enhance your ability to predict Biotechnology Portfolio's future price movements. Getting to know how Biotechnology Portfolio's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Biotechnology Portfolio may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| FSPHX | Health Care Portfolio | (0.96) | 1 per month | 0.00 | (0.07) | 1.43 | (1.07) | 6.87 | |
| FSPTX | Technology Portfolio Technology | 0.05 | 1 per month | 1.06 | 0.05 | 2.11 | (2.13) | 6.12 | |
| FSELX | Semiconductors Portfolio Semiconductors | 0.47 | 2 per month | 1.44 | 0.14 | 3.49 | (2.21) | 11.46 | |
| FSCSX | Software And It | (0.52) | 2 per month | 0.00 | (0.06) | 1.57 | (2.56) | 5.92 |
Biotechnology Portfolio Additional Predictive Modules
Most predictive techniques to examine Biotechnology price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Biotechnology using various technical indicators. When you analyze Biotechnology charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Biotechnology Portfolio Predictive Indicators
The successful prediction of Biotechnology Portfolio stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Biotechnology Portfolio Biotechnology, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Biotechnology Portfolio based on analysis of Biotechnology Portfolio hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Biotechnology Portfolio's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Biotechnology Portfolio's related companies. Story Coverage note for Biotechnology Portfolio
The number of cover stories for Biotechnology Portfolio depends on current market conditions and Biotechnology Portfolio's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Biotechnology Portfolio is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Biotechnology Portfolio's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
View All Premium Stories
Check out Biotechnology Portfolio Basic Forecasting Models to cross-verify your projections. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.